Tuberculosis

Accelerating impact of long-acting technologies in low- and middle-income countries (LMICs)

Grant Source: 
UNITAID

Safe and efficacious medicines are available for the prevention and treatment of major diseases, but their effectiveness can be compromised by poor treatment completion. Lack of adherence can worsen clinical outcomes, leading to increased mortality, persistent transmission and increased drug resistance in the case of antimicrobials and antivirals. Analyses of treatment and prevention of HIV, malaria, and TB within public health programs show wide disparities in rates of completion, especially among specific populations and regions.

Application Deadline: 23 April 2019

Health Topics: 
HIV
LA/ER Implantable Therapy
LA/ER Injectable Therapy
LA/ER Oral Therapy
Tuberculosis

    Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling

    Date: 
    12/19/18
    Citation: 

    Rajoli RKR, Curley P, Chiong J, et al. Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling. J Infect Dis. 2019 May 5;219(11):1735-1742. doi: 10.1093/infdis/jiy726. PMID: 30566691; PMCID: PMC6500558.

    Cabotegravir and rilpivirine are two long-acting (LA) ARVs that can be administered intramuscularly (IM); their interaction with rifampicin, a first-line anti-TB agent, has not been investigated. The aim of this study was to simulate and predict DDIs between these LA ARV agents and rifampicin using PBPK modelling.

    Health Topics: 
    HIV
    LA/ER Injectable Therapy
    Tuberculosis

      Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study

      Date: 
      8/17/18
      Citation: 

      Rajoli RKR, PodanyAT, Moss DM, et al. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):937-944. PMID: 29991405; PMCID: PMC6166436.

      SETTING:
      Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues.

      OBJECTIVE:
      niazid, rifapentine, bedaquiline and delamanid—in adults for treatment for latent tuberculous infection (LTBI).

      Health Topics: 
      LA/ER Implantable Therapy
      LA/ER Injectable Therapy
      Tuberculosis

        Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?

        Date: 
        8/17/18
        Citation: 

        Dooley KE. Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time? Int J Tuberc Lung Dis. 2018 Aug 1;22(8):833-34. DOI: https://doi.org/10.5588/ijtld.18.0411.

        Tuberculosis (TB) is a wily and enduring foe, responsible for 1 billion deaths in the last 200 years. With the introduction of antibiotics active against Mycobacterium tuberculosis in the 1950s, TB disease could finally be cured with multidrug therapy. TB drugs must still be given for months, generally via directly observed therapy, which is intrusive, expensive, and inconvenient.

        Health Topics: 
        Tuberculosis

          Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges

          Date: 
          2/15/18
          Citation: 

          Swindells S, Siccardi M, Barrett SE, et al. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018 Feb 1; 22(2): 125–132. PMID: 29506608; PMCID: PMC6103451.

          Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to anti-tuberculosis treatment could have substantial impact. 

          Health Topics: 
          HIV
          LA/ER Injectable Therapy
          Tuberculosis

            Pages